171 related articles for article (PubMed ID: 24772915)
21. The epigenetic modifier, valproic acid, enhances radiation sensitivity.
Karagiannis TC; Kn H; El-Osta A
Epigenetics; 2006; 1(3):131-7. PubMed ID: 17965607
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic targeting of glioma stem cells: Short-term and long-term treatments with valproic acid modulate DNA methylation and differentiation behavior, but not temozolomide sensitivity.
Riva G; Butta V; Cilibrasi C; Baronchelli S; Redaelli S; Dalprà L; Lavitrano M; Bentivegna A
Oncol Rep; 2016 May; 35(5):2811-24. PubMed ID: 26986767
[TBL] [Abstract][Full Text] [Related]
23. Effect of Combined Epigenetic Treatments and Ectopic NIS Expression on Undifferentiated Thyroid Cancer Cells.
Massimino M; Tirrò E; Stella S; Frasca F; Vella V; Sciacca L; Pennisi MS; Vitale SR; Puma A; Romano C; Manzella L
Anticancer Res; 2018 Dec; 38(12):6653-6662. PubMed ID: 30504373
[TBL] [Abstract][Full Text] [Related]
24. Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression.
Song Y; Zhang C
Cancer Chemother Pharmacol; 2009 Mar; 63(4):605-13. PubMed ID: 18521605
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia.
Cervera E; Candelaria M; López-Navarro O; Labardini J; Gonzalez-Fierro A; Taja-Chayeb L; Cortes J; Gordillo-Bastidas D; Dueñas-González A
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):207-12. PubMed ID: 22420986
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic drugs take on cancer.
Kaiser J
Science; 2010 Oct; 330(6004):576-8. PubMed ID: 21030620
[No Abstract] [Full Text] [Related]
27. Targeting epigenetic DNA and histone modifications to treat kidney disease.
Fontecha-Barriuso M; Martin-Sanchez D; Ruiz-Andres O; Poveda J; Sanchez-Niño MD; Valiño-Rivas L; Ruiz-Ortega M; Ortiz A; Sanz AB
Nephrol Dial Transplant; 2018 Nov; 33(11):1875-1886. PubMed ID: 29534238
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic modifiers 5-aza-2'-deoxycytidine and valproic acid differentially change viability, DNA damage and gene expression in metastatic and non-metastatic colon cancer cell lines.
Ghecham A; Senator A; Pawlowska E; Bouafia W; Błasiak J
Acta Biochim Pol; 2019 Jul; 66(3):355-360. PubMed ID: 31284710
[TBL] [Abstract][Full Text] [Related]
29. Radiosensitizing potential of epigenetic anticancer drugs.
De Schutter H; Nuyts S
Anticancer Agents Med Chem; 2009 Jan; 9(1):99-108. PubMed ID: 19149485
[TBL] [Abstract][Full Text] [Related]
30. Sensitization of suberoylanilide hydroxamic acid (SAHA) on chemoradiation for human cervical cancer cells and its mechanism.
Xing J; Wang H; Xu S; Han P; Xin M; Zhou JL
Eur J Gynaecol Oncol; 2015; 36(2):117-22. PubMed ID: 26050346
[TBL] [Abstract][Full Text] [Related]
31. Sodium valproate, a histone deacetylase inhibitor, enhances the efficacy of vinorelbine-cisplatin-based chemoradiation in non-small cell lung cancer cells.
Gavrilov V; Lavrenkov K; Ariad S; Shany S
Anticancer Res; 2014 Nov; 34(11):6565-72. PubMed ID: 25368259
[TBL] [Abstract][Full Text] [Related]
32. Transcriptional Selectivity of Epigenetic Therapy in Cancer.
Sato T; Cesaroni M; Chung W; Panjarian S; Tran A; Madzo J; Okamoto Y; Zhang H; Chen X; Jelinek J; Issa JJ
Cancer Res; 2017 Jan; 77(2):470-481. PubMed ID: 27879268
[TBL] [Abstract][Full Text] [Related]
33. Epigenetics in radiotherapy: where are we heading?
Smits KM; Melotte V; Niessen HE; Dubois L; Oberije C; Troost EG; Starmans MH; Boutros PC; Vooijs M; van Engeland M; Lambin P
Radiother Oncol; 2014 May; 111(2):168-77. PubMed ID: 24861629
[TBL] [Abstract][Full Text] [Related]
34. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate.
Chávez-Blanco A; De la Cruz-Hernández E; Domínguez GI; Rodríguez-Cortez O; Alatorre B; Pérez-Cárdenas E; Chacón-Salinas R; Trejo-Becerril C; Taja-Chayeb L; Trujillo JE; Contreras-Paredes A; Dueñas-González A
Int J Oncol; 2011 Dec; 39(6):1491-9. PubMed ID: 21805029
[TBL] [Abstract][Full Text] [Related]
35. Different Schedule-Dependent Effects of Epigenetic Modifiers on Cytotoxicity by Anticancer Drugs in Colorectal Cancer Cells.
Hosokawa M; Tanaka S; Ueda K; Iwakawa S
Biol Pharm Bull; 2017 Dec; 40(12):2199-2204. PubMed ID: 28954936
[TBL] [Abstract][Full Text] [Related]
36. Enhanced inhibition of clonogenic survival of human medulloblastoma cells by multimodal treatment with ionizing irradiation, epigenetic modifiers, and differentiation-inducing drugs.
Patties I; Kortmann RD; Menzel F; Glasow A
J Exp Clin Cancer Res; 2016 Jun; 35(1):94. PubMed ID: 27317342
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic agents in combined anticancer therapy.
Kejík Z; Jakubek M; Kaplánek R; Králová J; Mikula I; Martásek P; Král V
Future Med Chem; 2018 May; 10(9):1113-1130. PubMed ID: 29676175
[TBL] [Abstract][Full Text] [Related]
38. HDAC inhibitors show differential epigenetic regulation and cell survival strategies on p53 mutant colon cancer cells.
R M; P HA; Mahadevan V
J Biomol Struct Dyn; 2018 Mar; 36(4):938-955. PubMed ID: 28264628
[TBL] [Abstract][Full Text] [Related]
39. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy.
Segura-Pacheco B; Trejo-Becerril C; Perez-Cardenas E; Taja-Chayeb L; Mariscal I; Chavez A; Acuña C; Salazar AM; Lizano M; Dueñas-Gonzalez A
Clin Cancer Res; 2003 May; 9(5):1596-603. PubMed ID: 12738711
[TBL] [Abstract][Full Text] [Related]
40. [Possibilities of epigenetic anti-tumor therapy in in-vitro models].
Kovalëv RA; Stam TA; Ibatulin FM; Bondarev GN; Filatov MV
Vopr Onkol; 2012; 58(6):800-7. PubMed ID: 23600307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
